ClinicalTrials.gg
CompletedNCT05772520Updated Jul 21, 2026Results posted

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

A Phase 2 interventional study of TLL018 tablets in Plaque Psoriasis, sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
325th of 673
82 · median 77
Started
2023
with 31 others
Phase 2
200 of 764
5 open now
Registered
680th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 325th largest by enrollment of the 673 interventional ones that give a count, is one of 32 that started in 2023, is one of 200 in phase 2, and was the 680th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are between the ages of 18 and 75 years, inclusive, at time of .
  2. Capable of giving informed consent and complying with study procedures.
  3. Willing and able to adhere to study restrictions.
  4. Laboratory and medical history parameters within the protocol defined ranges.
  5. Normal renal function (>90 mL/min/1.72 m2) or mild renal impairment (Stage 2 mild chronic kidney disease [GFR] = 60 to 89 mL/min/1.73 m2) as determined by central laboratory.
  6. (BMI) of 18.0 to 35.0 kg/m2 inclusive.
  7. Have had a diagnosis of moderate-to-severe PP for at least 6 months prior to Baseline.
  8. Participants with moderate-to-severe PP covering ≥10% body surface area (BSA), with a Psoriasis Area and Severity Index (PASI) ≥12 and a static Physician's Global Assessment (PGA) score ≥3 at Baseline.
  9. Participants with plaque psoriasis who are systemic treatment naïve or have received at least one of the conventional anti-psoriasis treatments such as acitretin, phototherapy, methotrexate, cyclosporine, apremilast, or biologic therapy (anti-TNF or anti-IL-12/17/23).
  10. Participants who are candidates for systemic treatment for psoriasis at the discretion of the Investigator.
  11. Must agree to avoid prolonged exposure (> 15 minutes) to the sun and avoid use of tanning booths or other ultraviolet light sources during the study.
  12. Female participants of (See Section 10.4.1 definition of Woman of Childbearing Potential - WOCBP) must have a negative serum human chorionic gonadotropin (hCG) at Screening, and meet one of the following criteria:

    1. Using a medically acceptable form of (Appendix 4) for at least 1 month prior to Screening and 3 months after the last dose of study drug (e.g., hormonal contraceptives [oral, patch, injectable or vaginal ring], implantable device [implantable rod or intrauterine device], bilateral tubal occlusion/tubal ligation, azoospermic partner).
    2. Abstinence as a form of birth control is generally not permitted during the study with the exception of participants who practice abstinence as a preferred and usual lifestyle style choice. The Investigator must confirm that abstinence is still in accordance with the participant's lifestyle at regular intervals throughout the study.
  13. Male participants with female partners of childbearing potential must agree to use condoms for the duration of the study and until 13 weeks after administration of the study intervention and must refrain from donating sperm for this same period. In addition, his female partner should agree to use a highly effective method of birth control per Appendix 4 or an additional barrier form of birth control (e.g., diaphragm, cervical cap, spermicide, or sponge).)
  14. Ability to swallow and retain oral study intervention.
  15. Participants must have completed their coronavirus disease 2019 (COVID-19) vaccination in accordance with the latest CDC guidelines, which is based on previous vaccination history. Please reference COVID-19 vaccination guidance for individuals who are moderately or severely (Clinical Guidance for COVID-19 Vaccination \| CDC).

    1. Previous Pfizer-BioNTech, Moderna or Novavax: Must have previously received at least a 1st and 2nd dose, then must have received an updated formulation according to the CDCs dosing requirements; or
    2. Novavax or Johnson and Johnson's Janssen: Must have previously received 1 or more doses in combination with any original monovalent or bivalent COVID-19 vaccine doses, then must receive an updated formulation according to the CDCs vaccination guidelines.

Exclusion criteria

...

Exclusion Criteria:

  1. Pregnant or nursing women.
  2. Past history of gastrointestinal perforation, history of peptic ulcers and/or regular use of NSAIDs.
  3. History of chronic alcohol or drug abuse within 6 months prior to Screening as determined by the Investigator based on medical history and patient interview.
  4. Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, neurologic, or psychiatric disease.
  5. Current and/or recent history (\<30 days prior to Screening and/or \<45 days prior to randomization) of a viral, bacterial, fungal, parasitic, or mycobacterial infection.
  6. Subject is currently being treated with or has received strong cytochrome P450 3A () inhibitors, such as itraconazole, within 4 weeks prior to Baseline (Day 0).
  7. Any history of , except for non-recurrent basal cell skin cancer, squamous cell skin cancer, and cervical cancer in situ that are considered to be cured.
  8. Tests positive for , , or (HIV). For Hepatitis B all subjects will undergo testing for Hepatitis B Surface Antigen (HBsAg) and Hepatitis B Core Antibody (HBcAb). Subjects who are HBsAg positive are not eligible for the study. Subjects who are HBsAg negative and HBcAb positive will subsequently need testing for Hepatitis B virus deoxyribonucleic acid (HBV DNA) and if HBV DNA negative may be enrolled in the study; if HBV DNA is positive, the subject is not eligible for the study. Positive hepatitis C virus result is defined as having a positive hepatitis C antibody test with a positive confirmatory hepatitis C polymerase chain reaction test.
  9. Recent exposure to active tuberculosis (TB). Current evidence of active TB or current evidence of latent TB. Participants with positive TB test (e.g., QuantiFERON) that have been treated for latent TB. A borderline QuantiFERON test should be repeated. If still indeterminant, then a chest x-ray may be performed (positive chest x-ray is exclusionary).
  10. History of unexplained syncope, symptomatic hypotension, or hypoglycemia.
  11. Abnormal D-dimer levels in conjunction with clinical or current and past thrombotic disease.
  12. Participants with uncontrolled hypertension, uncontrolled diabetes, untreated or uncontrolled hyperlipidemia (fasting blood triglycerides >500 mg/dL and fasting cholesterol >250 mg/dL).
  13. History of any significant cardiac event (e.g., myocardial infarction) within 6 months prior to Screening, including:

    1. History of long syndrome; history or presence of an abnormal , which, in the Investigator's opinion, is clinically significant.
    2. History of unstable ischemic heart disease or uncontrolled hypertension.
    3. Current Class 3 or 4 heart failure per the Functional Classification.
    4. Screening and/or Baseline QTcF > 450 msec for males and > 470 msec for females, confirmed by triplicate ECG.
  14. Participants with history of thrombosis and/ or thromboembolism, or associated risk factors (e.g., inherited thrombophilias, etc.).
  15. Donated or lost >500 mL of blood in the previous 3 months.
  16. Participants with chronic kidney disease with \<60 mL/min/1.73 m2.
  17. Participants with moderate-to-severe hepatic impairment (i.e., Class B and C).
  18. Major surgery within 3 months prior to Screening or participant has a planned major surgery during the course of the study.
  19. Participants with any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary:

    • \<100 g/L
    • White blood cell (WBC) count of \<3.0 × 109/L
    • count of \<80 × 109/L
    • of \<1.5 × 109/L
    • (AST) or alanine aminotransferase (ALT) values greater than 3 times the
  20. Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the participant's participation in the study.
  21. Previous or current diseases (e.g., RA, systemic lupus erythematosus, IBD, scleroderma, inflammatory myopathy, mixed connective tissue disease overlap syndrome, etc.). Note, psoriatic arthritis patients are allowed.
  22. Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, drug-induced psoriasis).
  23. Current enrollment in another study intervention protocol or experimental treatment within 30 days or five half-lives (whichever is longer).
  24. Received any topical therapy that can affect psoriasis (including topical use of moderate-strong , retinoids, vitamin D3 derivatives, salicylic acid, anthracene, etc.) within 2 weeks of first study intervention. Low potency topical steroids are permitted for sensitive areas only (e.g., face, axillae, genitalia). Bland emollients without urea or α or β-hydroxy acids are permitted.
  25. Use of phototherapy (including photochemotherapy, ultraviolet therapy, tanning bed self-therapy, etc.) within 4 weeks of first study intervention.
  26. Use of systemic oral therapy that can affect psoriasis (including but not limited to glucocorticoids, retinoids, cyclosporine, methotrexate and apremilast) within 4 weeks of first study intervention.
  27. Received intravenous corticosteroids within 4 weeks of first study intervention.
  28. Use of antimalarial drugs, interferon-α, lithium and beta-blockers within 4 weeks of first study intervention.
  29. Use of Chinese or herbal medicine treatment of psoriasis within 2 weeks of first study intervention.
  30. Prior to randomization, of the following biologics are required: etanercept ≥28 days; any s.c. mAb targeting TNF (eg., infliximab, adalimumab, certolizumab) >3 months; ustekinumab or drugs that specifically target IL-23>6 months; secukinumab, ixekizumab, bimekizumab, brodalumab or other IL-17 antagonists >6 months; any other anti-psoriasis treatments not listed within 5 half-lives. Topical JAK inhibitors should have a washout period > 2 weeks.
  31. Prior use of three or more biologic therapies.
  32. Use of natalizumab and other drugs that regulate B or T cells within 12 months of first study intervention, such as rituximab, alemtuzumab, and abatacept.
  33. Participants who have received within 2 months prior to first study intervention or plan to receive live vaccines during the study period. Non-live-attenuated vaccines (e.g., ribonucleic acid [RNA]-based vaccines, inactivated adenovirus-based vaccines, protein-based vaccines), including non-live-attenuated vaccines or boosters for coronavirus disease 2019 (COVID-19) during the study are allowed.
  34. Participants who have received COVID-19 vaccines within 2 weeks of Baseline or participants who plan to receive COVID-19 vaccines during the study period (boosters are allowed).
  35. Previously not completed COVID-19 vaccination in accordance with the CDC guidelines.
  36. Participants who are allergic to any component of the study intervention or who are at risk for allergy as determined by the Investigator during the study.
  37. Any condition for which the Investigator considers the participant inappropriate to participate in this study.

    ....

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Cohort 2

    TLL018 tables, 20 mg 1piece,BID

    Drug: TLL018 tablets

  • Experimental
    Cohort 3

    TLL018 tables, 40 mg 1piece,BID

    Drug: TLL018 tablets

  • Experimental
    Cohort 4

    placebo, 1piece,BID

    Drug: TLL018 tablets

Interventions

  • oral tablets administered 20 mg BID and 40 mg BID for 12 weeks

    Also known as: TLL018 Placeboes

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving PASI-75 (FAS)

    A PASI 75 response is defined as achieving at least a 75% improvement (reduction) in the Psoriasis Area and Severity Index (PASI) score from baseline. The PASI is a composite tool that assesses the overall severity of erythema, induration, and scaling, as well as the extent of body surface area involvement. The total PASI score ranges from 0 to 72, with higher scores indicating more severe disease. The results are in Full Analysis Set (FAS).

    Time frame: Week12

  2. Proportion of Participants Achieving PASI 75 (PPS)

    A PASI 75 response is defined as achieving at least a 75% improvement (reduction) in the Psoriasis Area and Severity Index (PASI) score from baseline. The PASI is a composite tool that assesses the overall severity of erythema, induration, and scaling, as well as the extent of body surface area involvement. The total PASI score ranges from 0 to 72, with higher scores indicating more severe disease. The results are in Per-Protocol Set. Excludes participants with major protocol violations.

    Time frame: Week12

07

Results

Posted Jul 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started3129814
Completed2423810
Not completed7604

Outcome measures

PrimaryProportion of Participants Achieving PASI-75 (FAS)

A PASI 75 response is defined as achieving at least a 75% improvement (reduction) in the Psoriasis Area and Severity Index (PASI) score from baseline. The PASI is a composite tool that assesses the overall severity of erythema, induration, and scaling, as well as the extent of body surface area involvement. The total PASI score ranges from 0 to 72, with higher scores indicating more severe disease. The results are in Full Analysis Set (FAS).

Time frame:
Week12
Reported as:
Count of participants · Participants
Proportion of Participants Achieving PASI-75 (FAS)
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Proportion of Participants Achieving PASI-75 (FAS)111343
PrimaryProportion of Participants Achieving PASI 75 (PPS)

A PASI 75 response is defined as achieving at least a 75% improvement (reduction) in the Psoriasis Area and Severity Index (PASI) score from baseline. The PASI is a composite tool that assesses the overall severity of erythema, induration, and scaling, as well as the extent of body surface area involvement. The total PASI score ranges from 0 to 72, with higher scores indicating more severe disease. The results are in Per-Protocol Set. Excludes participants with major protocol violations.

Time frame:
Week12
Reported as:
Count of participants · Participants
Proportion of Participants Achieving PASI 75 (PPS)
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Proportion of Participants Achieving PASI 75 (PPS)91142

Adverse events

Collected over AEs were collected from informed consent up to 4 weeks after the last dose of study drug (up to a total of 16 weeks). Displays of treatment-emergent AEs (TEAEs) are provided using the Safety population.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/31 (0%)0/31 (0%)14/31 (45.2%)
Cohort 20/29 (0%)0/29 (0%)10/29 (34.5%)
Cohort 30/8 (0%)0/8 (0%)1/8 (12.5%)
Cohort 40/14 (0%)0/14 (0%)11/14 (78.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4
NasopharyngitisInfections and infestations1/310/291/80/14
Alanine aminotransferase increasedInvestigations2/313/290/81/14
Blood pressure increasedInvestigations1/310/290/81/14
Blood triglycerides increasedInvestigations0/311/290/81/14
Activated partial thromboplastin time prolongedInvestigations0/310/290/81/14
InfluenzaInfections and infestations1/311/290/81/14
Urinary tract infectionInfections and infestations1/310/290/81/14
Viral infectionInfections and infestations0/310/290/81/14
MigraineNervous system disorders0/310/290/81/14
Food poisoningGastrointestinal disorders0/310/290/81/14

Baseline characteristics

Full Analysis Set (FAS), including all randomized participants.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Total
Mean47.9 ± 14.047.1 ± 14.849.3 ± 10.743.9 ± 14.647.1 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Female1371728
Male18227754
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
American Indian or Alaska Native21003
Asian12227
Native Hawaiian or Other Pacific Islander10001
Black or African American32016
White232461164
More than one race00000
Unknown or Not Reported10001
Body Surface Area
Body Surface Area(Percentage of BSA)Cohort 1Cohort 2Cohort 3Cohort 4Total
Mean27.42 ± 15.5322.01 ± 13.0921.38 ± 12.4328.11 ± 14.3725.03 ± 14.26
PASI score
PASI score(units on a scale)Cohort 1Cohort 2Cohort 3Cohort 4Total
Mean19.40 ± 8.0116.47 ± 5.6917.36 ± 7.2120.11 ± 6.8018.29 ± 7.02
PGA score category
PGA score category(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Score 3 (Moderate)16197850
Score 4 (Severe)15101632
08

Study locations

35 sites
  • Cahaba
    Birmingham, Alabama 35244, United States
  • Moy, Fincher, Chipps
    Beverly Hills, California 90210, United States
  • Metropolis Derm
    Los Angeles, California 90017, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Integrative Skin
    Sacramento, California 95815, United States
  • Skin Surgical
    San Diego, California 92117, United States
  • Life Clinical Trials
    Coral Springs, Florida 33071, United States
  • Palm Beach
    DeLand, Florida 33484, United States
  • D&H Doral Research Center LLC
    Doral, Florida 33122, United States
  • Sweet Hope Research Specialty, Inc
    Hialeah, Florida 33016, United States
  • CNS - Jacksonville
    Jacksonville, Florida 32256, United States
  • CNS - Orlando SODO
    Jacksonville, Florida 32256, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Anchor Medical Research, LLC (Core Clinical Trials)
    Miami, Florida 33176, United States
  • Reserka Research
    Miami, Florida 33176, United States
  • ForCare Medical (CenExcel)
    Tampa, Florida 33613, United States
  • Integrated Clinical Trial Services, Inc
    Des Moines, Iowa 50265, United States
  • IMA Clinical Research
    Monroe, Louisiana 71201, United States
  • Lawrence Green
    Rockville, Maryland 20850, United States
  • Metro Boston
    Brighton, Massachusetts 02135, United States
  • Oakland Hills Dermatology
    Auburn Hills, Michigan 48326, United States
  • Revival Research Institute
    Troy, Michigan 48084, United States
  • Grekin Skin
    Warren, Michigan 48088, United States
  • Minnesota Clinical Study Center
    New Ulm, Minnesota 55112, United States
  • Mount Sinai
    New York, New York 10003, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Remington-Davis, Inc.
    Columbus, Ohio 43215, United States
  • DermDox
    Sugarloaf, Pennsylvania 18249, United States
  • CRCC
    Charleston, South Carolina 29407, United States
  • Dermatology Associates of Knoxville
    Knoxville, Tennessee 37909, United States
  • Derm Research
    Austin, Texas 78759, United States
  • Studies in Dermatology, LLC
    Cypress, Texas 77433, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Progressive Clinical Research Group, Inc.
    San Antonio, Texas 78213, United States
  • Acclaim
    Sugar Land, Texas 77479, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2024, 22 months.

Results were first posted in Jul 2026, 1 year 7 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 22 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 16, 2023
StartActual
Jan 19, 2023
Primary completionActual
Dec 1, 2024
CompletionActual
Dec 23, 2024
Results first posted
Jul 21, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05772520
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
Jan 19, 2023
Primary completion
Dec 1, 2024
Completion
Dec 23, 2024
Results posted
Jul 21, 2026
Last update
Jul 21, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLL-018

Start the discussion